1. In Vivo
  2. >>Market Access

Trump's Sights Set On Payers And Pharmas, But Medtechs Must Not Be Complacent

 
• By Ashley Yeo

It's been a big month for plans intended to shape the future of health care in the US, with the Trump Administration showcasing its ACA replacement bill and issuing budget proposals. At this stage, it's hard to peg winners and losers and although the focus is squarely on insurance, the medtech sector should guard against complacency, says ZS Associates' Brian Chapman.

Capitol House

A month after Donald Trump's election as US President last November, In Vivo asked Brian Chapman, ZS Associates' principal and leader of the firm's medical products consulting practice, for an early take on how medtech businesses and the sector in general would be affected by decisions likely to emerge from the new US administration and its three-line Republican monopoly. (Also see "US Medtech Under Trump: Below The Radar Or In The Line Of Fire?" - In Vivo, 12 December, 2016.)

At that early stage, it was hard to make any predictions, although the laser focus was already on insurance reform....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.